CIK 0001984086 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Septerna, Inc.
Sign in to watch- Ticker
- SEPN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843891440
- Phone
- 650-338-3533
- Business address
- 250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,210,085
- in 3 filings, $4.2M under 10b5-1 plans
Net −$4,210,085. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-01 | Long Daniel D. SVP, Drug Discovery | Option exercise 10b5-1 | +3,333 | $2.76 | $9K | 99,745 |
| 2026-09-01 | Long Daniel D. SVP, Drug Discovery | Sale 10b5-1 | −3,333 | $37.83 | $126K | 96,412 |
| 2026-09-01 | Long Daniel D. SVP, Drug Discovery | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,333 | 9,085 | ||
| 2026-08-03 | Long Daniel D. SVP, Drug Discovery | Option exercise 10b5-1 | +1,816 | $2.76 | $5K | 98,228 |
| 2026-08-03 | Long Daniel D. SVP, Drug Discovery | Option exercise 10b5-1 | +1,518 | $2.76 | $4K | 99,746 |
| 2026-08-03 | Long Daniel D. SVP, Drug Discovery | Sale 10b5-1 | −1,000 | $33.98 | $34K | 98,746 |
| 2026-08-03 | Long Daniel D. SVP, Drug Discovery | Sale 10b5-1 | −2,334 | $34.68 | $81K | 96,412 |
| 2026-08-03 | Long Daniel D. SVP, Drug Discovery | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,816 | 5,227 | ||
| 2026-08-03 | Long Daniel D. SVP, Drug Discovery | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,518 | 12,418 | ||
| 2026-07-01 | Long Daniel D. SVP, Drug Discovery | Option exercise 10b5-1 | +3,333 | $2.76 | $9K | 99,745 |
| 2026-07-01 | Long Daniel D. SVP, Drug Discovery | Sale 10b5-1 | −2,100 | $34.10 | $72K | 97,645 |
| 2026-07-01 | Long Daniel D. SVP, Drug Discovery | Sale 10b5-1 | −1,233 | $34.81 | $43K | 96,412 |
| 2026-07-01 | Long Daniel D. SVP, Drug Discovery | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,333 | 7,043 | ||
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Option exercise 10b5-1 | +10,529 | $2.76 | $29K | 106,941 |
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Option exercise 10b5-1 | +4,471 | $11.70 | $52K | 111,412 |
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Sale 10b5-1 | −8,000 | $35.10 | $281K | 103,412 |
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Sale 10b5-1 | −7,000 | $35.97 | $252K | 96,412 |
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,529 | 10,376 | ||
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,471 | 25,529 | ||
| 2026-02-06 | Long Daniel D. SVP, Drug Discovery | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 |
Page 1 of 2 · 22 trades